Regulatory change monitoring in life sciences is becoming increasingly complex as global and regional health authorities issue a growing volume of guidance across multiple formats and jurisdictions. Agencies such as the FDA, EMA, MHRA, PMDA, and Health Canada, as well as regulators in emerging markets, release frequent, often unscheduled updates that affect submissions, labeling, quality systems, and post-approval obligations. Manual approaches, based on spreadsheets, alerts, and periodic reviews, are no longer sufficient to ensure timely interpretation, consistent impact assessment, or inspection readiness.

CES 2026 marked a structural shift in how consumer technology is being built and commercialized. The industry is moving beyond “smart devices” toward coordinated living systems, where intelligence is distributed across homes, vehicles, wearables, and networks to deliver outcomes with minimal user effort.